Halozyme Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de Halozyme Therapeutics' es Helen Torley , nombrado en Jan 2014, tiene una permanencia de 10.25 años. compensación anual total es $11.82M, compuesta por 7.8% salario y 92.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.53% de las acciones de la empresa, por valor de $26.20M. La antigüedad media del equipo directivo y de la junta directiva es de 2.2 años y 10.3 años, respectivamente.

Información clave

Helen Torley

Chief Executive Officer (CEO)

US$11.8m

Compensación total

Porcentaje del salario del CEO	7.8%
Permanencia del CEO	10.3yrs
Participación del CEO	0.5%
Permanencia media de la dirección	2.2yrs
Promedio de permanencia en la Junta Directiva	10.3yrs

Actualizaciones recientes de la dirección

Recent updates

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 23

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Jan 26

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Jan 10

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Dec 14

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Sep 22

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jul 04

We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

May 09

Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Mar 28

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Jan 23

Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Dec 09

Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Oct 24

Here's Why We Think Halozyme Therapeutics (NASDAQ:HALO) Might Deserve Your Attention Today

Sep 08

Halozyme Therapeutics raises $625M through convertible senior notes due 2028

Aug 16

Halozyme Therapeutics: One To Put On Your 'Shopping List' For The Next Market Sell-Off

Aug 03

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Jul 26

Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Jun 10

Halozyme: Antares Pharma Bolsters Growth Prospects

May 19

Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Apr 25

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Helen Torley en comparación con los beneficios de Halozyme Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$12m	US$920k	US$282m
Sep 30 2023	n/a	n/a	US$254m
Jun 30 2023	n/a	n/a	US$234m
Mar 31 2023	n/a	n/a	US$182m
Dec 31 2022	US$10m	US$872k	US$202m
Sep 30 2022	n/a	n/a	US$211m
Jun 30 2022	n/a	n/a	US$366m
Mar 31 2022	n/a	n/a	US$435m
Dec 31 2021	US$7m	US$830k	US$403m
Sep 30 2021	n/a	n/a	US$409m
Jun 30 2021	n/a	n/a	US$229m
Mar 31 2021	n/a	n/a	US$163m
Dec 31 2020	US$7m	US$791k	US$129m
Sep 30 2020	n/a	n/a	US$22m
Jun 30 2020	n/a	n/a	-US$40m
Mar 31 2020	n/a	n/a	-US$80m
Dec 31 2019	US$6m	US$761k	-US$72m
Sep 30 2019	n/a	n/a	-US$40m
Jun 30 2019	n/a	n/a	-US$43m
Mar 31 2019	n/a	n/a	-US$51m
Dec 31 2018	US$6m	US$725k	-US$80m
Sep 30 2018	n/a	n/a	US$46m
Jun 30 2018	n/a	n/a	US$76m
Mar 31 2018	n/a	n/a	US$68m
Dec 31 2017	US$5m	US$671k	US$63m

Compensación vs. Mercado: La compensación total de Helen($USD11.82M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD8.42M).

Compensación vs. Ingresos: La compensación de Helen ha aumentado más de un 20% en el último año.

CEO

Helen Torley (60 yo)

10.3yrs

Permanencia

US$11,820,858

Compensación

Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. Prior to joining Halozyme in January 2014, she served as the...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Helen Torley	President	10.3yrs	US$11.82m	0.53% $ 26.4m
Nicole LaBrosse	Senior VP & CFO	2.2yrs	US$3.85m	0.012% $ 603.1k
Michael LaBarre	Senior VP & Chief Technical Officer	no data	US$3.24m	0.13% $ 6.6m
Mark Snyder	Senior VP & Chief Legal Officer	2.3yrs	US$3.61m	0.0092% $ 455.0k
Cortney Caudill	Chief Operations Officer	less than a year	sin datos	sin datos
Tram Bui	Head of Investor Relations & Corporate Communications	2.3yrs	sin datos	sin datos
Amy Fox	Senior Vice President of Human Resources	4.3yrs	sin datos	sin datos
Kristin Schwartzbauer	Head of Quality	no data	sin datos	sin datos
Gary Grote	Chief Commercial Officer	less than a year	sin datos	sin datos
Christopher Wahl	Chief Business Officer	less than a year	sin datos	sin datos

2.2yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de HALO se considera experimentado (2.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Helen Torley	President	10.3yrs	US$11.82m	0.53% $ 26.4m
Connie Matsui	Independent Director	17.8yrs	US$460.02k	0.14% $ 7.0m
Jeffrey Henderson	Independent Chair of the Board	8.7yrs	US$555.02k	0.031% $ 1.5m
Daniel Von Hoff	Member of the Scientific Advisory Board	19.7yrs	sin datos	sin datos
Jeffrey Bleil	Member of the Advisory Board	no data	sin datos	sin datos
Gregory Frost	Chairman of Scientific Advisory Board	10.3yrs	US$68.17k	sin datos
Gerhard Baumgartner	Member of Scientific Advisory Board	19.8yrs	sin datos	sin datos
Sue Bailey	Member of Scientific Advisory Board	18.8yrs	sin datos	sin datos
Matthew Posard	Independent Director	11.1yrs	US$471.83k	0.078% $ 3.9m
Jean-Pierre Bizzari	Independent Director	9.3yrs	US$458.48k	0.046% $ 2.3m
Bernadette Connaughton	Independent Director	5.6yrs	US$470.02k	0.020% $ 1.0m
Moni Miyashita	Independent Director	2.1yrs	US$455.02k	0.0049% $ 241.6k

10.3yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de HALO son experimentados ( 10.3 años antigüedad media).

Halozyme Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Senior VP & Chief Technical Officer exercised options and sold US$606k worth of stock

Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024

Senior VP & Chief Technical Officer exercised options and sold US$612k worth of stock

Senior VP & Chief Technical Officer notifies of intention to sell stock

President exercised options and sold US$735k worth of stock

President exercised options and sold US$601k worth of stock

Recent updates

Senior VP & Chief Technical Officer exercised options and sold US$606k worth of stock

Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics

Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Senior VP & Chief Technical Officer exercised options and sold US$612k worth of stock

Senior VP & Chief Technical Officer notifies of intention to sell stock

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS exceeds analyst expectations

President exercised options and sold US$735k worth of stock

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

President exercised options and sold US$601k worth of stock

Halozyme Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023

Halozyme Announces Takeda Receives FDA Approval for Hyqvia® Co-Formulated with Enhanze® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces Roche Receives European Commission Approval of Tecentriq®? SC with ENHANZE®? Representing the EU's First Subcutaneous PD(L)1 Cancer Immunotherapy for Multiple Cancer Types

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Senior VP & Chief Technical Officer exercised options and sold US$544k worth of stock

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Senior VP & Chief Technical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS exceeds analyst expectations

Halozyme Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Halozyme Therapeutics, Inc. Reports Positive Topline Results from the Phase 3 Checkmate-67T Trial Evaluating Subcutaneous (SC) Formulation of Opdivo (Nivolumab) with Enhanze

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Therapeutics, Inc Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

Independent Director recently sold US$875k worth of stock

Independent Director notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023

Halozyme Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Senior VP & Chief Technical Officer notifies of intention to sell stock

Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Positive Results Announces from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo With ENHANZE for Subcutaneous Use in Generalized Myasthenia Gravis

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2023

We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

Senior VP & Chief Technical Officer notifies of intention to sell stock

Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Insufficient new directors

Price target decreased by 7.1% to US$52.11

Investor sentiment deteriorates as stock falls 16%

President notifies of intention to sell stock

Independent Director recently sold US$962k worth of stock

Chief Technical Officer notifies of intention to sell stock

Consensus EPS estimates fall by 10%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

President exercised options and sold US$1.1m worth of stock

Halozyme Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Halozyme Therapeutics Appoints Barbara Duncan to Its Board of Directors

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

President exercised options and sold US$1.1m worth of stock

Halozyme Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2023

General Counsel exercised options and sold US$155k worth of stock

President exercised options and sold US$1.3m worth of stock

Independent Director recently sold US$1.7m worth of stock

Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Independent Director notifies of intention to sell stock

President exercised options and sold US$1.2m worth of stock

CFO & Director recently sold US$269k worth of stock

Price target increased to US$51.63